ASCO: Sorafenib Slows Progression in Advanced Thyroid Cancer

Data presented at ASCO from the phase III DECISION trial showed treatment with the TKI sorafenib (Nexavar) delayed disease progression by 5 months in patients with metastatic differentiated thyroid cancer that had progressed on radioactive iodine.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news